Werewolf Therapeutics, Inc.
HOWL
$0.63
-$0.03-4.32%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | 0.00 |
| Cost of Revenue | 6.18M | 10.86M | 973.00K | 12.32M | 14.93M |
| Gross Profit | -6.18M | -10.86M | -973.00K | -12.32M | -14.93M |
| SG&A Expenses | 3.24M | 4.86M | 5.18M | 5.68M | 5.42M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.42M | 15.73M | 17.54M | 17.99M | 20.35M |
| Operating Income | -9.42M | -15.73M | -17.54M | -17.99M | -20.35M |
| Income Before Tax | -8.38M | -16.37M | -17.98M | -18.09M | -20.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.38M | -16.37M | -17.98M | -18.09M | -20.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.38M | -16.37M | -17.98M | -18.09M | -20.40M |
| EBIT | -9.42M | -15.73M | -17.54M | -17.99M | -20.35M |
| EBITDA | -9.02M | -15.32M | -17.14M | -17.57M | -19.91M |
| EPS Basic | -0.17 | -0.36 | -0.40 | -0.40 | -0.46 |
| Normalized Basic EPS | -0.11 | -0.22 | -0.25 | -0.25 | -0.29 |
| EPS Diluted | -0.20 | -0.36 | -0.40 | -0.40 | -0.46 |
| Normalized Diluted EPS | -0.11 | -0.22 | -0.25 | -0.25 | -0.29 |
| Average Basic Shares Outstanding | 48.43M | 45.80M | 44.98M | 44.83M | 44.48M |
| Average Diluted Shares Outstanding | 49.22M | 45.80M | 44.98M | 44.83M | 44.48M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |